Related Experiment Video
Updated: Dec 24, 2025
06:54
MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
Published on: September 3, 2013
11.6K
Gadolinium-based nanoscale MRI contrast agents for tumor imaging
1CAS Key Laboratory of Nano-Bio Interface, Division of Nanobiomedicine, Suzhou Institute of Nano-Tech and Nano-Bionics, Chinese Academy of Sciences, Suzhou 215123, China. rjpei2011@sinano.ac.cn.
Journal of Materials Chemistry. B
|April 9, 2020
Summary
Gadolinium-based nanoscale contrast agents show promise for detecting tumor tissue using magnetic resonance imaging. These agents enhance imaging signals by concentrating gadolinium ions and adding functionalities for improved medical diagnosis.
Area of Science:
- Nanotechnology
- Medical Imaging
- Oncology
Background:
- Gadolinium-based nanoscale contrast agents (CAs) are increasingly important for medical diagnosis.
- They offer enhanced longitudinal relaxivity (r1) and targeted delivery of gadolinium ions.
- Nanoplatforms allow for the incorporation of diverse functionalities.
Purpose of the Study:
- To review the latest developments in gadolinium-based nanoscale MRI CAs.
- To highlight current applications of these agents in tumor detection.
- To provide perspectives on future research and development.
Main Methods:
- Literature review of recent advancements in nanoscale gadolinium contrast agents.
- Analysis of studies focusing on MRI applications for tumor detection.
- Synthesis of information on functionalization and relaxivity enhancement.
Main Results:
- Gadolinium-based nanoplatforms significantly improve MRI contrast for tumor detection.
- Enhanced relaxivity and targeted delivery are key advantages.
- Versatile functionalization enables multimodal imaging and therapeutic applications.
Conclusions:
- Nanoscale gadolinium contrast agents represent a significant advancement in medical diagnosis.
- Continued development is expected to yield more effective tumor detection and treatment strategies.
- Future research should focus on optimizing agent design and clinical translation.
